体外受精与胚胎植入前非整倍体检测后无创产前检测结果的解读
本研究为回顾性队列研究,纳入2014至2019年在大学附属生殖中心接受体外受精、胚胎植入前非整倍体检测并移植单个整倍体胚胎后行无创产前检测的1139例患者。其中8例无创产前检测阳性,阳性预测值为12.5%。提示该人群胎儿非整倍体风险较低,无创产前检测阳性预测值低于一般人群。
要点
- 移植整倍体胚胎后无创产前检测阳性预测值仅12.5%,显著低于一般人群的约69%。
- 8例阳性中6例诊断性检测证实为整倍体,1例Turner综合征阳性经羊膜腔穿刺确诊为嵌合体。
- 临床医生应向患者说明该人群无创产前检测阳性预测值较低,避免过度解读阳性结果。
核心结论
- 移植整倍体胚胎的患者胎儿非整倍体风险相对低于一般人群,无创产前检测阳性预测值在该人群中较低。
研究设计与样本
- 回顾性队列研究,纳入2014至2019年大学附属生殖中心接受体外受精、胚胎植入前非整倍体检测并移植单个整倍体胚胎后行无创产前检测的1139例患者。
主要发现
- 1139例中8例无创产前检测阳性,其中6例后续诊断性检测显示整倍体核型与胚胎植入前非整倍体检测结果一致,1例未行诊断性检测并分娩正常婴儿。
- 1例无创产前检测提示Turner综合征者经羊膜腔穿刺确诊为Turner嵌合体(45,X核型占80%细胞)。
- 该队列无创产前检测阳性预测值为12.5%。
关键数值与推荐
- 一般人群无创产前检测阳性预测值约为69%。
- 本队列无创产前检测阳性预测值为12.5%。
临床怎么用
- 临床医生应告知移植整倍体胚胎的患者其胎儿非整倍体风险相对较低,无创产前检测阳性预测值较低。
- 对无创产前检测阳性结果应谨慎解读,并结合诊断性检测确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The positive predictive value of noninvasive prenatal testing is approximately 69% in the general population. However, positive predictive value is dependent on the prevalence of the disease in the population being tested. Patients who undergo in vitro fertilization with preimplantation genetic testing for aneuploidy and transfer a euploid embryo are presumably a lower risk population than the general population. OBJECTIVE: In this study, we explored the positive predictive value of noninvasive prenatal testing in women undergoing in vitro fertilization with preimplantation genetic testing for aneuploidy and subsequent transfer of a euploid embryo. STUDY DESIGN: This study was a retrospective cohort study. All patients who underwent in vitro fertilization with preimplantation genetic testing for aneuploidy followed by transfer of a single euploid embryo between 2014 and 2019 at a university-affiliated fertility center were contacted. Noninvasive prenatal testing results were reviewed and those with positive noninvasive prenatal testing were identified. Results of any subsequent prenatal or postnatal diagnostic testing were used to classify each positive noninvasive prenatal testing as a true positive or a false positive. The prevalence and positive predictive value of positive noninvasive prenatal testing was calculated. RESULTS: A total of 1139 patients that underwent noninvasive prenatal testing after transfer of a euploid embryo were identified, 8 of which had positive noninvasive prenatal testing screens. Although 6 of these patients had subsequent definitive prenatal diagnostic testing that revealed a euploid karyotype concordant with their preimplantation genetic testing for aneuploidy results, 1 patient opted out of diagnostic testing and later delivered a normal baby. Of note, 1 patient who had noninvasive prenatal testing positive for Turner syndrome underwent amniocentesis, which confirmed Turner mosaicism (45,X karyotype in 80% of cells). Therefore, the positive predictive value of noninvasive prenatal testing in this patient cohort was 12.5%. CONCLUSION: Clinicians and patients should recognize that patients undergoing transfer of a euploid embryo are at a relatively lower risk for fetal aneuploidy than the general population, and the positive predictive value of noninvasive prenatal testing is lower in this setting.
引用
- Klimczak AM, Reig A, Neal SA, et al. Interpretation of noninvasive prenatal testing results following in vitro fertilization and preimplantation genetic testing for aneuploidy. Am J Obstet Gynecol MFM. 2020. PMID: 33345935. doi:10.1016/j.ajogmf.2020.100232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。